Claims

1-35. (canceled)

36. A method for preparing a novel vaccine formulation comprising the steps of:a) adding about one volume of oily phase to an emulsifier means,b) rotating said emulsifier means from about 4000 rpm to about 6000 rpm,c) adding about one volume of a first aqueous phase to the about one volume of oily phase to said emulsifier means while continuing to rotate said emulsifier means from about 30 seconds to about 2 minutes,d) stopping rotation of said emulsifier means,e) placing a resulting emulsion produced by said rotating at 5° C. for at least 4 hours,f) adding about one volume of a second aqueous phase at about 5° C. to about one volume of said resulting emulsion at about 5° C. and stirring for about 1 minute;wherein said oily phase comprises more than one surfactant; andwherein said second aqueous phase comprises at least one immunogen; andwherein the total weight of said more than one surfactant is about 0.75% to about 5.5% (w/v) of said novel vaccine formulation.

37. The method of claim 36, wherein said immunogen is selected from the group consisting of Salmonella typhimurium, Salmonella enteritidis, Infectious Bronchitis virus (IBV), Newcastle Disease virus (NDV), egg drop syndrome virus (EDS), or Infectious Bursal Disease virus (IBDV), and avian influenza virus.

38. The method of claim 36 wherein said at least one immunogen is selected from the group consisting of feline herpesvirus (FHV), feline calicivirus (FCV), feline leukemia virus (FeLV), and feline immunodeficiency virus (FIV).

39. The method of claim 36 wherein said at least one immunogen is selected from the group consisting of rabies virus, canine herpesvirus (CHV), canine parvovirus (CPV), canine coronavirus, Leptospira canicola, Leptospira icterohaemorragiae, Leptospira grippotyphosa, Borrelia burgdorferi, and Bordetella bronchiseptica.

40. The method of claim 36 wherein said at least one immunogen is selected from the group consisting of equine herpesvirus (type 1 or type 4), equine influenza virus, tetanus, and west nile virus.

41. The method of claim 36 wherein said at least one immunogen is selected from the group consisting of swine influenza virus (SIV), porcine circovirus type 2 (PCV-2), porcine reproductive respiratory syndrome virus (PRRS), pseudorabies virus (PRV), porcine parvovirus (PPV), Mycoplasma hyopneumoniae, Erysipelothrix rhusiopathiae, Pasteurella multocida, Bordetella bronchiseptica, and Escherichia coli.

42. The method of claim 36 wherein said at least one immunogen is selected from the group consisting of bovine rotavirus, bovine parainfluenza virus type 3 (bPIV-3), bovine coronavirus, bovine viral diarrhea virus (BVDV), bovine respiratory syncytial virus (BRSV), Infectious Bovine Rhinotracheitis virus (IBR), Escherichia coli, Pasteurella multocida, and Pasteurella haemolytica.

43. The method of claim 36 wherein said at least one immunogen is inactivated Mycoplasma hyopneumoniae or inactivated PCV-2.

44. The method of claim 36 wherein said at least one immunogen is inactivated Mannheimia haemolytica.